ReviewFrontiers in pharmacology2026
Toward the rational design of oncogenic TASK-3 channel inhibitor peptides and nanoconjugate complexes.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
TASK-3 potassium channels have emerged as important regulators in several aspects of cancer pathophysiology. Overexpression of TASK-3 occurs in a broad spectrum of cancers, including breast, lung, ovarian, colorectal cancers, and melanoma. Genetic or pharmacological inhibition of TASK-3 has been shown to suppress tumorigenic properties. Despite the strong evidence, the development of selective TASK-3 inhibitors remains limited. In this review, we analyze the current evidence supporting TASK-3 as an oncogenic target, with emphasis on peptide-based inhibitors and advanced delivery strategies. Also, we review the landscape of TASK-3 modulation across different cancer types, summarize known mechanisms of ion channel inhibition, and highlight the advantages of peptides for achieving target selectivity and specificity. We further explore nanoconjugate delivery systems to improve peptide stability, bioavailability, and tumor targeting. Finally, we outline rational design methods, phage display technologies, and electrophysiological validation as an integrated pipeline for developing next-generation TASK-3 inhibitors. Together, these approaches delineate a strategic and technical framework for advancing selective TASK-3-targeted therapeutics in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.